

Special Issue

Establishment and Characterization of Novel Patient-Derived Cancer Cell Line

Message from the Guest Editors

Patient-derived cancer cell lines have facilitated fundamental progress in cancer biology and revolutionized medicine. They enable functional studies of novel genes and proteins, allow the evaluation of anti-tumor effects of novel anti-cancer agents in a high-throughput manner, and provide insights into molecular mechanisms underlying the malignant behavior of cancer cells. The advent of genomics has identified a large number of intriguing genes, and such cell lines are required to interpret their functional properties and the significance of their aberrant regulation in the clinical tumors. Although cell lines are important tools in cancer research, several critical issues remain to be addressed to improve their utility and possible applications. The Special Issue will highlight the establishment and characterization of novel cell lines using clinical materials. Original contributions related to novel cell lines, characterization of novel and existing cell lines, technical notes for cell line establishment and application, and review articles of relevant topics are invited for publication in this Special Issue.

Guest Editors

Dr. Yuki Yoshimatsu

Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan

Dr. Tadashi Kondo

Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan

Deadline for manuscript submissions

closed (31 October 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/88527

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).